A PILOT STUDY OF P-2647, A NEW BENZOQUINOLIZINE DERIVATIVE EMPLOYED AS A PSYCHOTHERAPEUTIC AGENT IN 44 CASES OF OVERT ANXIETY
MARSHALL E. SMITH M.D.
P-2647, a new benzoquinolizine derivative, is structurally related to reserpine and tetrabenazine. It appears to possess unique ability to suppress conditioned avoidance behaviour without releasing central amines.
In this pilot study, P-2647 was administered to 44 anxious patients. Of these, 39 reported definite and significant reduction in anxiety. With the exception of mild sedation, no side effects were reported.
The results suggest that this new benzoquinolizine possesses a degree of psychotherapeutic activity and safety that makes it worthy of further investigation.
